Sharon Caunt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sharon Caunt has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Anni Sandbæk
Department of Clinical Research, Nordsjællands Hospital, DK
1 shared publication - Bastiaan E. de Galan
Department of Internal Medicine Radboud University Medical Centre Nijmegen the Netherlands
1 shared publication - Brian G. Keevil
Department of Clinical Biochemistry, Manchester University NHS Foundation Trust, Southmoor Rd 3
1 shared publication - Charlotte Jane Elder
Clinical Medicine, School of Medicine and Population Health, The University of Sheffield, Sheffield, UK
1 shared publication - Eric Renard
Institute of Functional Genomics, University of Montpellier, CNRS, INSERM, Montpellier, France
1 shared publication - Esben Søndergaard
Medical/Steno Aarhus Research Laboratory, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
1 shared publication
Latest Publications
- Open Access
- 30 December 2025
- Published by Wiley in Diabetic Medicine
- Vol. 43 (3) , e70185
User evaluation of the Hypo‐METRICS app: A tool for real‐time symptom reporting of hypoglycaemia
Aims: Hypoglycaemia remains a barrier to optimal diabetes management, with few tools for capturing real‐time person‐reported hypoglycaemia (PRH). This study evaluated the Hypo‐METRICS app, originally developed for a multinational 10‐week prospective study of hypoglycaemia. It enables real‐time reporting of hypoglycaemic episodes and their impact on daily functioning using Ecological Momentary Assessment (EMA), thereby overcoming limitations of retrospective self reports. Methods: After completing the Hypo‐METRICS study, 120 participants with type 1 diabetes mellitus (T1D) or type 2 diabetes mellitus (T2D) from Austria, Denmark, the Netherlands, and the United Kingdom were invited to complete a web‐based questionnaire assessing app content, functionality, intervention effects, user engagement and the influence of the Covid‐19 pandemic. Results: Ninety‐six participants (80%; 29 T1D, 67 T2D) completed the questionnaire (40% women; mean age 57.2 ± 16.1 years; 26% impaired hypoglycaemia awareness; HbA1c 60 ± 13 mmol/mol (7.6 ± 1.1%); diabetes duration 20.4 ± 11.3 years). App content and functionality were rated highly (>8/10 and >7/10, respectively). Some reported declining engagement, likely due to study length. COVID‐19 had a minimal impact on app use. Conclusions: The Hypo‐METRICS app was well accepted, with strong ratings for usability and functionality. Given its unique strengths, the app has the potential to become an essential instrument for researchers aiming to capture the real‐world burden and impact of hypoglycaemia.
- 30 December 2025
- Published by Wiley in Diabetic Medicine
- Vol. 43 (3) , e70185
Open AccessUser evaluation of the Hypo‐METRICS app: A tool for real‐time symptom reporting of hypoglycaemia
Aims: Hypoglycaemia remains a barrier to optimal diabetes management, with few tools for capturing real‐time person‐reported hypoglycaemia (PRH). This study evaluated the Hypo‐METRICS app, originally developed for a multinational 10‐week prospective study of hypoglycaemia. It enables real‐time reporting of hypoglycaemic episodes and their impact on daily functioning using Ecological Momentary Assessment (EMA), thereby overcoming limitations of retrospective self reports. Methods: After completing the Hypo‐METRICS study, 120 participants with type 1 diabetes mellitus (T1D) or type 2 diabetes mellitus (T2D) from Austria, Denmark, the Netherlands, and the United Kingdom were invited to complete a web‐based questionnaire assessing app content, functionality, intervention effects, user engagement and the influence of the Covid‐19 pandemic. Results: Ninety‐six participants (80%; 29 T1D, 67 T2D) completed the questionnaire (40% women; mean age 57.2 ± 16.1 years; 26% impaired hypoglycaemia awareness; HbA1c 60 ± 13 mmol/mol (7.6 ± 1.1%); diabetes duration 20.4 ± 11.3 years). App content and functionality were rated highly (>8/10 and >7/10, respectively). Some reported declining engagement, likely due to study length. COVID‐19 had a minimal impact on app use. Conclusions: The Hypo‐METRICS app was well accepted, with strong ratings for usability and functionality. Given its unique strengths, the app has the potential to become an essential instrument for researchers aiming to capture the real‐world burden and impact of hypoglycaemia.
- 12 January 2024
- Published by Elsevier in Canadian Journal of Diabetes
- Vol. 48 (3) , 204-210.e1
A Cross-sectional Study on the Impact of Educational Status on Physical Activity Level in Danish and English Adults With Type 1 Diabetes
- 12 January 2024
- Published by Elsevier in Canadian Journal of Diabetes
- Vol. 48 (3) , 204-210.e1
A Cross-sectional Study on the Impact of Educational Status on Physical Activity Level in Danish and English Adults With Type 1 Diabetes
- 27 October 2022
- Published by Bioscientifica in Endocrine Abstracts
- Vol. 86
Screening for adrenal insufficiency using home waking salivary cortisone is accurate and lowers NHS costs
Introduction: The 250µg Short Synacthen test (SST) is the reference standard for a diagnosis of adrenal insufficiency (AI) in most endocrine centres. The test is expensive and time consuming, requiring clinic attendance. We hypothesised that a cheaper home waking salivary cortisone (WSC) is predictive of the SST 30-minute cortisol >430 nmol/l cut-off and carried out a diagnostic accuracy study to assess the predictive value of the WSC in diagnosing and excluding AI. We then carried out a cost analysis to compare two diagnostic strategies: the SST vs a two stage WSC±SST. Methods: We recruited 220 patients prospectively and all patients collected a WSC (measured by LC-MS/MS) and a SST was carried out on the same day. Using ROC curves we computed diagnostic accuracy and then estimated Positive (PPV) and Negative Predictive Value (NPV). A decision analytic model was developed to describe the costs and outcomes associated with the SST vs WSC±SST. To obtain a societal perspective we also enquired about patient costs and time off work via questionnaire. Results: The WSC was a strong predictor of the SST 30-minute serum cortisol >430 nmol/L: AuROC (95% CI), 95% (92,97%). Using a cut-off of ≥17 nmol/l one could exclude AI with a NPV 96% (90%,99%) and using a cut-off of <7 nmol/l one could confirm AI with a PPV 95% (87%,99%). Based on these values, using the WSC as a screening test would obviate the need for an SST in 70% of subjects. The economic results for the primary analysis show that a two-stage diagnostic strategy would save £102.83 in costs per patient. When using a societal perspective this strategy costs £126.99 less than current SST testing. Conclusions: WSC is an accurate screening tool for AI and significantly reduces costs for the NHS. Home WSC should be introduced to clinical care.
- 27 October 2022
- Published by Bioscientifica in Endocrine Abstracts
- Vol. 86
Screening for adrenal insufficiency using home waking salivary cortisone is accurate and lowers NHS costs
Introduction: The 250µg Short Synacthen test (SST) is the reference standard for a diagnosis of adrenal insufficiency (AI) in most endocrine centres. The test is expensive and time consuming, requiring clinic attendance. We hypothesised that a cheaper home waking salivary cortisone (WSC) is predictive of the SST 30-minute cortisol >430 nmol/l cut-off and carried out a diagnostic accuracy study to assess the predictive value of the WSC in diagnosing and excluding AI. We then carried out a cost analysis to compare two diagnostic strategies: the SST vs a two stage WSC±SST. Methods: We recruited 220 patients prospectively and all patients collected a WSC (measured by LC-MS/MS) and a SST was carried out on the same day. Using ROC curves we computed diagnostic accuracy and then estimated Positive (PPV) and Negative Predictive Value (NPV). A decision analytic model was developed to describe the costs and outcomes associated with the SST vs WSC±SST. To obtain a societal perspective we also enquired about patient costs and time off work via questionnaire. Results: The WSC was a strong predictor of the SST 30-minute serum cortisol >430 nmol/L: AuROC (95% CI), 95% (92,97%). Using a cut-off of ≥17 nmol/l one could exclude AI with a NPV 96% (90%,99%) and using a cut-off of <7 nmol/l one could confirm AI with a PPV 95% (87%,99%). Based on these values, using the WSC as a screening test would obviate the need for an SST in 70% of subjects. The economic results for the primary analysis show that a two-stage diagnostic strategy would save £102.83 in costs per patient. When using a societal perspective this strategy costs £126.99 less than current SST testing. Conclusions: WSC is an accurate screening tool for AI and significantly reduces costs for the NHS. Home WSC should be introduced to clinical care.